Next 10 |
home / stock / trgnf / trgnf news
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shar...
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 month...
Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Lucie Larguier as Chief Financial Officer (CFO), effect...
Poster presentation of new data from ongoing randomized Phase I trial targeting head and neck cancers Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for t...
Strasbourg (France), Tokyo (Japan) and Waltham, Mass (USA), March 5 th , 2024, 7:30 am CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI...
Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer ...
Strasbourg (France), January 22, 2024 - 08:00 am CET TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2024. March 27, 2024: 2023 Fiscal Year Results May 14, 2024: First Quarter 2024 Financial Results May 15, 2024: Annual Shareholders' Meetin...
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of head and neck cancers Strasbourg, France & Tokyo, Japan, January 8, 2024, 5:45 ...
Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud D...
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shar...
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 month...